Skip to main content
. Author manuscript; available in PMC: 2018 Mar 1.
Published in final edited form as: Am J Hematol. 2017 Feb 3;92(3):238–243. doi: 10.1002/ajh.24625

Figure 2. Relapse-free survival for patients based on additional chromosomal abnormalities and tyrosine kinase inhibitor.

Figure 2

Relapse-free survival for patients with and without poor-risk additional chromosomal abnormalities treated with imatinib (A), dasatinib (B) or ponatinib (C).